Amarin (NASDAQ: AMRN)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Amarin Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Amarin Company Info
The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.
News & Analysis
Investors weren't happy with the company's decision to cease operations in a large country.
Although the company notched a revenue beat for its latest quarter, the bottom-line result fell short.
The drugmaker's downward spiral continued.
Investors continue to process disappointing data that was published on Thursday.
An activist investor is getting more active with the company.
The biopharmaceutical company's lowered revenue is scaring off investors.
Missed expectations on the top and bottom lines suggest Amarin's path forward isn't as clear as investors want it to be.
The biopharma couldn't escape the market-wide downturn this week.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Podcast Episodes
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
These healthcare stocks crushed the S&P 500's return last year, but that doesn't guarantee they'll be top performers in 2019.
Key trials suggest doctors may change how they treat patients with cardiovascular disease.
Earnings Transcripts
AMRN earnings call for the period ending June 30, 2022.
AMRN earnings call for the period ending March 31, 2022.
AMRN earnings call for the period ending December 31, 2021.
AMRN earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.